Generation of clinical grade human bone marrow stromal cells for use in bone regeneration.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25064527.
- Also identified by DOI 10.1016/j.bone.2014.07.020 and PMC identifier 4268331.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In current orthopaedic practice, there is a need to increase the ability to reconstruct large segments of bone lost due to trauma, resection of tumors and skeletal deformities, or when normal regenerative processes have failed such as in non-unions and avascular necrosis. Bone marrow stromal cells (BMSCs, also known as bone marrow-derived mesenchymal stem cells), when used in conjunction with appropriate carriers, represent a means by which to achieve bone regeneration in such cases. While much has been done at the bench and in pre-clinical studies, moving towards clinical application requires the generation of clinical grade cells. What is described herein is an FDA-approved cell manufacturing procedure for the ex vivo expansion of high quality, biologically active human BMSCs. This article is part of a Special Issue entitled Stem Cells and Bone.
Medical subject headings
- Bone Regeneration
- Cell Culture Techniques
- Mesenchymal Stem Cell Transplantation
- Mesenchymal Stem Cells